**2. Materials and Methods**

This prospective trial was registered in the German Clinical Trial Register (DRKS-ID: DRKS00014346) and approved by the institutional review board (registry no. 173/2015BO01) [24]. All participants provided written informed consent. A total of 69 consecutive patients with histopathologically confirmed cervical carcinoma and clinically determined stage ≤ FIGO IIB underwent whole-body dual-time-point [18F]FDG PET/MRI. A total of 63 of 69 participants underwent preoperative SLN mapping with SPECT/CT, followed by intraoperative SLN detection with a gamma probe and surgical staging between March 2016 and October 2020, and were included in the analysis (Figure 1).

**Figure 1.** Consort flow diagram. Data are given as numbers of patients with LNM/all patients in subgroups.
